121 related articles for article (PubMed ID: 29473975)
1. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Foster GR; Agarwal K; Cramp ME; Moreea S; Barclay S; Collier J; Brown AS; Ryder SD; Ustianowski A; Forton DM; Fox R; Gordon F; Rosenberg WM; Mutimer DJ; Du J; Gilbert CL; Asante-Appiah E; Wahl J; Robertson MN; Barr E; Haber B
Hepatology; 2018 Jun; 67(6):2113-2126. PubMed ID: 29473975
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
Elbasha EH; Robertson MN; Nwankwo C
Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
[TBL] [Abstract][Full Text] [Related]
3. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Sulkowski MS; Moon JS; Sherman KE; Morelli G; Darling JM; Muir AJ; Khalili M; Fishbein DA; Hinestrosa F; Shiffman ML; Di Bisceglie A; Rajender Reddy K; Pearlman B; Lok AS; Fried MW; Stewart PW; Peter J; Wadsworth S; Kixmiller S; Sloan A; Vainorius M; Horne PM; Michael L; Dong M; Evon DM; Segal JB; Nelson DR;
Hepatology; 2021 Dec; 74(6):2952-2964. PubMed ID: 34255381
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Feld JJ; Maan R; Zeuzem S; Kuo A; Nelson DR; Di Bisceglie AM; Manns MP; Sherman K; Frazier LM; Sterling R; Mailliard M; Schmidt M; Akushevich L; Vainorius M; Fried MW
Clin Infect Dis; 2016 Sep; 63(6):776-783. PubMed ID: 27325691
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
6. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
Kang YW; Baek YH; Lee SW; Park SJ; Yoon JS; Yoon KT; Hong Y; Heo NY; Seo KI; Lee SS; Cho HC; Shin JW
J Korean Med Sci; 2021 May; 36(21):e142. PubMed ID: 34060258
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions.
Dietz J; Vermehren J; Matschenz K; Buggisch P; Klinker H; Schulze Zur Wiesch J; Hinrichsen H; Peiffer KH; Graf C; Discher T; Trauth J; Schattenberg JM; Piecha F; Mauss S; Niederau C; Müller T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C;
Liver Int; 2020 Jul; ():. PubMed ID: 32640072
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E; Poordad F; Brainard DM; Hyland RH; An D; Dvory-Sobol H; Symonds WT; McHutchison JG; Membreno FE
Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Leroy V; Angus P; Bronowicki JP; Dore GJ; Hezode C; Pianko S; Pol S; Stuart K; Tse E; McPhee F; Bhore R; Jimenez-Exposito MJ; Thompson AJ
Hepatology; 2016 May; 63(5):1430-41. PubMed ID: 26822022
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
Elife; 2023 Jan; 12():. PubMed ID: 36622106
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Pérez AB; Chueca N; Macías J; Pineda JA; Salmerón J; Rivero-Juárez A; Hidalgo-Tenorio C; Espinosa MD; Téllez F; Von-Wichmann MÁ; Omar M; Santos J; Hernández-Quero J; Antón JJ; Collado A; Lozano AB; García-Deltoro M; Casado M; Pascasio JM; Selfa A; Rosales JM; De la Iglesia A; Arenas JI; García-Bujalance S; Ríos MJ; Bernal E; Martínez O; García-Herola A; Vélez M; Rincón P; García F
PLoS One; 2019; 14(8):e0221231. PubMed ID: 31469856
[TBL] [Abstract][Full Text] [Related]
14. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Lawitz E; Matusow G; DeJesus E; Yoshida EM; Felizarta F; Ghalib R; Godofsky E; Herring RW; Poleynard G; Sheikh A; Tobias H; Kugelmas M; Kalmeijer R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Sinha R; Witek J
Hepatology; 2016 Aug; 64(2):360-9. PubMed ID: 26704148
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Mei YY; Chen YM; Wu YK; Zhang XH; Xu WX
Can J Gastroenterol Hepatol; 2020; 2020():8872120. PubMed ID: 33194875
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Flamm S; Lawitz E; Borg B; Charlton M; Landis C; Reddy KR; Shiffman M; Alsina A; Chang C; Ravendhran N; Hernandez C; Hézode C; Scherbakovsky S; Mercier RC; Samuel D
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896803
[TBL] [Abstract][Full Text] [Related]
17. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
Yakoot M; Abdo AM; Abdel-Rehim S; Helmy S
EBioMedicine; 2017 Jul; 21():182-187. PubMed ID: 28647541
[TBL] [Abstract][Full Text] [Related]
18. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Kwo P; Gitlin N; Nahass R; Bernstein D; Etzkorn K; Rojter S; Schiff E; Davis M; Ruane P; Younes Z; Kalmeijer R; Sinha R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Witek J
Hepatology; 2016 Aug; 64(2):370-80. PubMed ID: 26799692
[TBL] [Abstract][Full Text] [Related]
19. Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done.
Llerena S; Cabezas J; Cuadrado A; Manuel Olmos J; González M; García F; Cobo C; Crespo J
Ann Hepatol; 2019; 18(1):236-239. PubMed ID: 31113598
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Kim YM; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB; Song MJ; Jang JW; Ko SY; Lee JD
Clin Mol Hepatol; 2018 Sep; 24(3):311-318. PubMed ID: 29865774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
